Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 7
http://www.senecabio.com
Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company’s stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidates include NSI-189, a chemical entity, which has been completed Phase II clinical trials for the treatment of major depressive disorder; and NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as in Phase II clinical trial for the treatment of chronic ischemic stroke and in Phase I clinical trial for the treatment of chronic spinal cord injury. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Need to check two numbers. 0.86/423.60% is expected bottom of this fall. 0.91/61.80% is 61.80% of upwave. Now 0.92 stayed slightly over 0.91. Good. Those number are critical support levels. Also 1.3/161.80% is important level for going high and FYI target price of this is 2.315/423.60%. In short, this stock is staying at bottom level and need go inside of 0.786 uptrend support line.
